The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score
Abstract Background Breast cancer (BC) remains the leading cause of cancer‐related deaths worldwide. High recurrence risk Luminal BC receives adjuvant chemotherapy in addition to standard hormone therapy. Considering the heterogeneity of Luminal B BC, a more accurate classification model is urgently...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850268781849346048 |
|---|---|
| author | Zheng‐Jun Yang Yu‐Xiao Liu Yue Huang Zu‐Jin Chen Hao‐Zhi Zhang Yue Yu Xin Wang Xu‐Chen Cao |
| author_facet | Zheng‐Jun Yang Yu‐Xiao Liu Yue Huang Zu‐Jin Chen Hao‐Zhi Zhang Yue Yu Xin Wang Xu‐Chen Cao |
| author_sort | Zheng‐Jun Yang |
| collection | DOAJ |
| description | Abstract Background Breast cancer (BC) remains the leading cause of cancer‐related deaths worldwide. High recurrence risk Luminal BC receives adjuvant chemotherapy in addition to standard hormone therapy. Considering the heterogeneity of Luminal B BC, a more accurate classification model is urgently needed. Methods In this study, we retrospectively reviewed the data of 1603 patients who were diagnosed with HER2‐negative breast invasive ductal carcinoma. According to the expression level of PR and Ki‐67 index, the Luminal B (HER2‐negative) BCs were divided into three groups: ER+PR−Ki67low (ER‐positive, PR‐negative, and Ki‐67 index <20%), ER+PR+Ki67high (ER‐positive, PR‐positive, and Ki‐67 index ≥20%), and ER+PR−Ki67high (ER‐positive, PR‐negative, and Ki‐67 index ≥20%). The cox proportional hazards regression model was used to evaluate the correlation between each variable and outcomes. Besides, discriminatory accuracy of the models was compared using the area under the receiver operating characteristic curve and log‐rank χ2 value. Results The analysis results showed that there was a significant correlation between subtypes using this newly defined classification and overall survival (p < 0.001) and disease‐free survival (DFS) (p < 0.001). Interestingly, patients in the ER+PR−Ki67high subgroup have the worst survival outcome in Luminal B (HER2‐negative) subtype, similar to Triple‐negative patients. Besides, the ER+PR+Ki67high has worse 5‐year DFS compared with Luminal A group. There was a significant relationship between the regrouping subtype and the recurrence score index (RI) (p < 0.001). Moreover, the results showed that patients in ER+PR–Ki67high subtype were more likely to have high RI for distance recurrence (RI‐DR) and local recurrence (RI‐LRR). Our newly defined classification has a better discrimination ability to predict survival outcome and recurrence score of Luminal B (HER2‐negative) BC patients, which may help in clinical decision‐making for individual treatment. |
| format | Article |
| id | doaj-art-ae01dda874fc498f8741e95d1c849d16 |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2023-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-ae01dda874fc498f8741e95d1c849d162025-08-20T01:53:22ZengWileyCancer Medicine2045-76342023-02-011232493250410.1002/cam4.5089The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence scoreZheng‐Jun Yang0Yu‐Xiao Liu1Yue Huang2Zu‐Jin Chen3Hao‐Zhi Zhang4Yue Yu5Xin Wang6Xu‐Chen Cao7The First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin ChinaThe First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin ChinaThe First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin ChinaThe First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin ChinaKey Laboratory of Cancer Prevention and Therapy Tianjin ChinaThe First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin ChinaThe First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin ChinaThe First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin ChinaAbstract Background Breast cancer (BC) remains the leading cause of cancer‐related deaths worldwide. High recurrence risk Luminal BC receives adjuvant chemotherapy in addition to standard hormone therapy. Considering the heterogeneity of Luminal B BC, a more accurate classification model is urgently needed. Methods In this study, we retrospectively reviewed the data of 1603 patients who were diagnosed with HER2‐negative breast invasive ductal carcinoma. According to the expression level of PR and Ki‐67 index, the Luminal B (HER2‐negative) BCs were divided into three groups: ER+PR−Ki67low (ER‐positive, PR‐negative, and Ki‐67 index <20%), ER+PR+Ki67high (ER‐positive, PR‐positive, and Ki‐67 index ≥20%), and ER+PR−Ki67high (ER‐positive, PR‐negative, and Ki‐67 index ≥20%). The cox proportional hazards regression model was used to evaluate the correlation between each variable and outcomes. Besides, discriminatory accuracy of the models was compared using the area under the receiver operating characteristic curve and log‐rank χ2 value. Results The analysis results showed that there was a significant correlation between subtypes using this newly defined classification and overall survival (p < 0.001) and disease‐free survival (DFS) (p < 0.001). Interestingly, patients in the ER+PR−Ki67high subgroup have the worst survival outcome in Luminal B (HER2‐negative) subtype, similar to Triple‐negative patients. Besides, the ER+PR+Ki67high has worse 5‐year DFS compared with Luminal A group. There was a significant relationship between the regrouping subtype and the recurrence score index (RI) (p < 0.001). Moreover, the results showed that patients in ER+PR–Ki67high subtype were more likely to have high RI for distance recurrence (RI‐DR) and local recurrence (RI‐LRR). Our newly defined classification has a better discrimination ability to predict survival outcome and recurrence score of Luminal B (HER2‐negative) BC patients, which may help in clinical decision‐making for individual treatment.https://doi.org/10.1002/cam4.5089breast cancerbreast cancer subtypeLuminal Bprognosisrecurrence score |
| spellingShingle | Zheng‐Jun Yang Yu‐Xiao Liu Yue Huang Zu‐Jin Chen Hao‐Zhi Zhang Yue Yu Xin Wang Xu‐Chen Cao The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score Cancer Medicine breast cancer breast cancer subtype Luminal B prognosis recurrence score |
| title | The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score |
| title_full | The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score |
| title_fullStr | The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score |
| title_full_unstemmed | The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score |
| title_short | The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score |
| title_sort | regrouping of luminal b her2 negative a better discriminator of outcome and recurrence score |
| topic | breast cancer breast cancer subtype Luminal B prognosis recurrence score |
| url | https://doi.org/10.1002/cam4.5089 |
| work_keys_str_mv | AT zhengjunyang theregroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT yuxiaoliu theregroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT yuehuang theregroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT zujinchen theregroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT haozhizhang theregroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT yueyu theregroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT xinwang theregroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT xuchencao theregroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT zhengjunyang regroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT yuxiaoliu regroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT yuehuang regroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT zujinchen regroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT haozhizhang regroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT yueyu regroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT xinwang regroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore AT xuchencao regroupingofluminalbher2negativeabetterdiscriminatorofoutcomeandrecurrencescore |